期刊
LANCET
卷 374, 期 9701, 页码 1617-1625出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(09)61302-7
关键词
-
资金
- Programme Hospitalier de Recherche Clinique National [AOM05157]
- Association Francois Aupetit
- Delegation Interregionale de la Recherche Clinique Ile de France-Assistance Publique Hopitaux de Paris
- Ligue contre le Cancer
- Fonds de Recherche de la Societe Nationale Francaise de Gastro-enterologie
Background Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. Methods 19486 patients with inflammatory bowel disease, of whom 11759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine exposure. Median follow-up was 35 months (IQR 29-40). Findings At baseline, 5867 (30.1%) of patients were receiving, 2809 (14.4%) had discontinued, and 10810 (55.5%) had never received thiopurines. 23 new cases of lymphoproliferative disorder were diagnosed, consisting of one case of Hodgkin's lymphoma and 22 cases of non-Hodgkin lymphoproliferative disorder. The incidence rates of lymphoproliferative disorder were 0.90 per 1000 (95% CI 0.50-1.49) patient-years in those receiving, 0.20/1000 (0.02-0.72) patient-years in those who had discontinued, and 0.26/1000 (0.10-0.57) patient-years in those who had never received thiopurines (p=0.0054). The multivariate-adjusted hazard ratio of lymphoproliferative disorder between patients receiving thiopurines and those who had never received the drugs was 5.28 (2.01-13.9, p=0.0007). Most cases associated with thiopurine exposure matched the pathological range of post-transplant disease. Interpretation Patients receiving thiopurines for inflammatory bowel disease have an increased risk of developing lymphoproliferative disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据